• Radius Announces Update on Tymlos (abaloparatide) Label Drugs
    December 29, 2021
    Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that the U.S. Food and Drug Administration (FDA) has approved updates to the Tymlos label, including the removal of the boxed warning regarding the risk of osteosarcoma.
PharmaSources Customer Service